aripiprazole has been researched along with cariprazine in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (67.74) | 24.3611 |
| 2020's | 10 (32.26) | 2.80 |
| Authors | Studies |
|---|---|
| Gmeiner, P; Hübner, H; Kling, RC; Leuner, K; Möller, D; Skultety, M | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Albert, JS; Johnstone, S | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Cheng, J; Fan, L; Liu, R; Tan, L; Wang, H; Wang, S; Yan, W; Yu, J | 1 |
| Bojarski, AJ; Dehaen, W; Janousek, J; Juza, R; Karasova, JZ; Kobrlova, T; Korabecny, J; Kubacka, M; Mezeiova, E; Mogilski, S; Musilek, K; Pejchal, J; Petrasek, T; Prchal, L; Randakova, A; Satala, G; Soukup, O; Stark, H; Stefkova-Mazochova, K; Svozil, D; Vlcek, P; Vojtechova, I | 1 |
| Adham, N; Agai-Csongor, E; Bugovics, G; Domány, G; Fazekas, K; Gyertyán, I; Hornok, K; Horváth, A; Kiss, B; Laszlovszky, I; Némethy, Z; Orosz, S; Schmidt, E; Szombathelyi, Z; Tihanyi, K | 1 |
| Caccia, S | 1 |
| Forbes, RA; Kikuchi, T; McQuade, RD; Tadori, Y | 1 |
| Gyertyán, I; Kiss, B; Román, V; Sághy, K; Szombathelyi, Z | 1 |
| Adham, N; Gruca, P; Gyertyán, I; Kiss, B; Lasoń-Tyburkiewicz, M; Papp, M | 1 |
| Citrome, L | 2 |
| Cutler, AJ; Durgam, S; Laszlovszky, I; Lu, K; Meltzer, HY; Migliore, R; Németh, G; Ruth, A | 1 |
| Adham, N; Fone, KCF; Gyertyán, I; King, MV; Kiss, B; Watson, DJG | 1 |
| Canals, M; Capuano, B; Charlton, SJ; Christopoulos, A; Coudrat, T; Donthamsetti, P; Javitch, JA; Klein Herenbrink, C; Lane, JR; Scammells, PJ; Sexton, PM; Shonberg, J; Sykes, DA | 1 |
| Adham, N; Choi, YK; Gyertyán, I; Kiss, B; Tarazi, FI | 1 |
| Adham, N; Banasr, M; Duman, RS; Duric, V; Franklin, T; Gyertyán, I; Kiss, B; Lepack, A | 1 |
| Augusto, M; Greene, M; Sweeney, SM; Touya, M; Waters, H | 2 |
| Barabássy, Á; Daniel, D; Durgam, S; Earley, W; Guo, H; Nasrallah, H; Németh, G; Patel, M; Szatmári, B; Zhong, Y | 1 |
| Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR | 1 |
| Azorin, JM; Simon, N | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Copolov, D; Hope, J; Keks, N; McLennan, H; Meadows, G; Schwartz, D | 1 |
| Aguirre, C; Garcia, M; Lertxundi, U; Morera-Herreras, T; Zazu, L | 1 |
| Husak, N; Laudone, TW; Leonard, JB | 1 |
| Keightley, P; Naughton, S; Nelson, J; O'Hara, K | 1 |
| Cain, K; Chung, I; Hardy, RE; Hirst, J; Loh, SHY; MacFarlane, M; Martins, LM; Morone, N; Panman, L; Pryde, KR; Serreli, R; Soleilhavoup, C; Travaglio, M; Yu, Y | 1 |
8 review(s) available for aripiprazole and cariprazine
| Article | Year |
|---|---|
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective.
Topics: Allosteric Regulation; Chemistry, Pharmaceutical; Humans; Ligands; Structure-Activity Relationship | 2017 |
Pharmacokinetics and metabolism update for some recent antipsychotics.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Drug Interactions; Humans; Inactivation, Metabolic; Isoindoles; Lurasidone Hydrochloride; Piperazines; Quinolones; Thiazoles | 2011 |
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine | 2016 |
Use of cariprazine in psychiatric disorders: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Piperazines; Risperidone; Schizophrenia | 2018 |
Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Dopamine Agonists; Humans; Piperazines; Receptors, Dopamine; United States; United States Food and Drug Administration | 2019 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiophenes | 2020 |
Aripiprazole, brexpiprazole, and cariprazine can affect milk supply: Advice to breastfeeding mothers.
Topics: Animals; Aripiprazole; Breast Feeding; Dopamine Agonists; Female; Humans; Milk; Mothers | 2023 |
3 trial(s) available for aripiprazole and cariprazine
| Article | Year |
|---|---|
Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Schizophrenia | 2015 |
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Drug Costs; Female; Humans; Injections, Intramuscular; Male; Markov Chains; Middle Aged; Paliperidone Palmitate; Piperazines; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Young Adult | 2018 |
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Young Adult | 2019 |
20 other study(ies) available for aripiprazole and cariprazine
| Article | Year |
|---|---|
Functionally selective dopamine D₂, D₃ receptor partial agonists.
Topics: Animals; Antipsychotic Agents; Arrestins; beta-Arrestin 2; beta-Arrestins; CHO Cells; Cricetulus; Drug Partial Agonism; GTP-Binding Protein alpha Subunits, Gi-Go; HEK293 Cells; Heterocyclic Compounds, 2-Ring; Humans; Mice; Molecular Docking Simulation; Oximes; Piperazines; Pyrazoles; Radioligand Assay; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereoisomerism; Structure-Activity Relationship; Swine | 2014 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
2-Phenylcyclopropylmethylamine Derivatives as Dopamine D
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Dopamine Agonists; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Mice; Mice, Inbred ICR; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 2021 |
Novel D
Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2022 |
Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Aripiprazole; Brain; Cell Line; Cricetinae; Cricetulus; Cyclic AMP; Dopamine; Dopamine D2 Receptor Antagonists; Drug Partial Agonism; Guinea Pigs; Humans; In Vitro Techniques; Inositol Phosphates; Male; Mice; Piperazines; Quinolones; Radioligand Assay; Rats; Receptors, Dopamine D3; Receptors, Histamine H1; Receptors, Serotonin; Recombinant Proteins; Reserpine; Serotonin | 2010 |
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
Topics: Animals; Aripiprazole; CHO Cells; Clozapine; Cricetinae; Cricetulus; Cyclic AMP; Dopamine; Drug Partial Agonism; Humans; Organic Chemicals; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Substrate Specificity | 2011 |
Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Cocaine-Related Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Haloperidol; Male; Piperazines; Quinolones; Rats; Rats, Long-Evans; Receptors, Dopamine D2; Secondary Prevention; Substance-Related Disorders | 2013 |
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Dietary Sucrose; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Imipramine; Male; Piperazines; Quinolones; Rats, Wistar; Stress, Psychological | 2014 |
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes | 2015 |
The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
Topics: Analysis of Variance; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Association Learning; Developmental Disabilities; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Interpersonal Relations; Locomotion; Male; Memory Disorders; Phencyclidine; Piperazines; Rats; Recognition, Psychology; Schizophrenia | 2016 |
The role of kinetic context in apparent biased agonism at GPCRs.
Topics: Animals; Aripiprazole; CHO Cells; Cricetulus; Dopamine; Dopamine Agonists; Indoles; Kinetics; Ligands; Piperazines; Piperidines; Principal Component Analysis; Protein Stability; Receptors, Dopamine D2 | 2016 |
Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Male; Piperazines; Prosencephalon; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate; Time | 2017 |
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
Topics: Anhedonia; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Aripiprazole; Chronic Disease; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Imipramine; Male; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Receptors, Dopamine D3; Stress, Psychological; Uncertainty | 2017 |
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Budgets; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzocycloheptenes; Drug Administration Schedule; Drug Costs; Health Care Costs; Heterocyclic Compounds, 4 or More Rings; Hospitalization; Humans; Injections, Intramuscular; Injections, Subcutaneous; Medication Adherence; Paliperidone Palmitate; Piperazines; Schizophrenia | 2018 |
Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study.
Topics: Antipsychotic Agents; Aripiprazole; Piperazines; Quinolones; Thiophenes | 2021 |
A descriptive study of aripiprazole, brexpiprazole, and cariprazine exposures in children ages 0 to 5 years reported to United States poison centers.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Poisons; Retrospective Studies; United States | 2023 |
Cariprazine (Vraylar) for adjunctive treatment of depression.
Topics: Antipsychotic Agents; Aripiprazole; Depression; Humans; Piperazines | 2023 |
The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drosophila melanogaster; Electron Transport; Mice | 2023 |